What information must be adequate to support a proposed clinical trial?

• A. The available nonclinical and clinical information on an investigational product(s) must be adequate.
• B. The recruitment plan and budget.
• C. Manufacturing quality control data.
• D. The marketing strategy.

Answer: (A)

The trial can proceed only when there is sufficient, appropriate information about the investigational product to justify testing in humans. This means having adequate nonclinical and clinical data that address safety and potential efficacy, and that support the proposed study design, dosing, and risk assessment. The information is typically organized in the Investigator’s Brochure and includes preclinical pharmacology and toxicology, pharmacokinetics and pharmacodynamics, any prior clinical experience, and a scientific rationale for the trial. This foundation helps protect participants by informing safety monitoring and dosing decisions, and it justifies the ethical and scientific basis for exposing humans to the investigational product.

Recruitment plans and budget relate to feasibility and resources, not to the safety and scientific justification of the trial. Manufacturing quality control data are important for product quality and supply, but they don’t by themselves establish that the trial is scientifically and ethically supported. Marketing strategy is not relevant to the trial’s clinical justification or participant safety.